Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.32%
SPX
-0.01%
IXIC
+0.05%
FTSE
+0.22%
N225
-0.21%
AXJO
+1.37%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

SLP is now overvalued and could go down -32%

Apr 28, 2025, 12:00 PM
-9.16%
What does SLP do
Simulations Plus, based in Lancaster, California, offers modeling software and consulting services for drug discovery, employing 192 staff and providing 12 software products and various pharmacokinetic services. Their expertise spans from early drug development to regulatory submissions and includes training solutions for clinical trials.
Based on our analysis, Simulations Plus has received an overvalued rating of 1 out of 5 stars from Cashu. Several key financial ratios indicate that the company may not be performing as well as it appears, particularly when compared to its sector. The Price-to-Earnings (PE) Ratio for Simulations Plus is remarkably high at 98.34, far exceeding the sector average of 13.90. A high PE ratio can suggest that a stock is overvalued or that investors are expecting high growth rates in the future. However, such a significant disparity raises concerns about the sustainability of growth and the potential for price corrections. Additionally, the Price-to-Book (PB) Ratio stands at 3.98, compared to the sector's average of 2.64. This indicates that investors are paying a premium for each dollar of net assets. A high PB ratio may signal overvaluation, especially if the company does not demonstrate corresponding growth in its asset base. While Simulations Plus does show strong profitability metrics, such as a net profit margin of 14.22, which is favorable compared to the sector's average of -138.43, the company's return on equity (ROE) of 5.46 is still low when juxtaposed against the sector's average of -75.69. This suggests that the company is not generating sufficient returns on shareholder equity relative to its peers. In summary, the high PE and PB ratios, coupled with a low ROE, indicate potential overvaluation of Simulations Plus in the market. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!